The Full Story in Plain English
What the Study Found (In Plain English)
For decades, the standard of care for patients with resected stage II and III colon cancer has centred on surgery with consideration of postoperative adjuvant systemic therapy to reduce risk of recurrence. Mismatch repair deficiency is seen in 10–15% of non-metastatic colon cancers and is predictive of response to immune checkpoint inhibition. The initial report of the single-arm, phase 2 NICHE-2 study of one dose of ipilimumab (1 mg per kg) and two doses of nivolumab (3 mg per kg) before surgery with clinical stage II and III colon cancer generated considerable interest after demonstrating a remarkable 98% pathologic response rate, including a pathologic complete response rate of 68%. Indexed from The Lancet (2026-10-21) by DotMD's 2-hour clinical surveillance pipeline.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Published in The Lancet (2026-10-21) • Study Design: Peer-Reviewed Journal (Clinical Trials) • Participants: Pooled Clinical Review • Biostatistical Rigor Score: 90/100. Primary Takeaway: Mismatch repair deficiency is seen in 10–15% of non-metastatic colon cancers and is predictive of response to immune checkpoint inhibition.
Study Limitations & Caveats Before You Act
While this peer-reviewed journal (clinical trials) scored 90/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.
Formal Peer-Reviewed Study Reference
“[Comment] Redefining curative treatment for early-stage mismatch repair-deficient colon cancer”
Published in The Lancet (2026-10-21) • PMID/ID: LANCET-668991693